Literature DB >> 14730554

Measurement of cytotoxic activity in experimental cancer.

Nayara Delgado Andre1, Décio Sabbatini Barbosa, Egberto Munhoz, Dirceu Estevão, Rubens Cecchini, Maria Angelica Ehara Watanabe.   

Abstract

Several tumor cell systems have been developed for investigating the cytotoxic activity of different substances. The Ehrlich ascytic tumor (EAT) has been studied extensively and used to increase our comprehension of immunotherapy (Yamamoto and Naraparaju. Cancer Res 57:2187-2192, 1997). In this study, we evaluated the ability of an enzymatic method to assess cytotoxic tumor activity in vitro. To prepare cytotoxic cells, lymphoid cells isolated from the lymph nodes of C57BL/6 mice were activated with interleukin-2 (IL-2). The cytotoxic activity to EAT cells was assessed by an enzymatic test using lactate dehydrogenase (LDH), an enzyme widely distributed in mammalian tissues which, in the presence of NAD/NADH, converts lactate to pyruvate. IL-2 treatment of lymph node cells induced a greater percentage of lysis (75.47%) than effector cells that were not treated with IL-2 (42.38%). This suggests that IL-2 directly activates effector cells and not tumor cells. The results demonstrate that the LDH release-measurement method can be utilized to assay cytotoxic cell-mediated activity in which murine tumor cells act as the target. Levels of IL-2 appear to have a direct correlation to cellular immunity and treatment with these substances may strengthen immune function and decrease the pace of disease development. Copyright 2004 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14730554      PMCID: PMC6807731          DOI: 10.1002/jcla.20006

Source DB:  PubMed          Journal:  J Clin Lab Anal        ISSN: 0887-8013            Impact factor:   2.352


  10 in total

1.  Lactate dehydrogenase activity as a rapid and sensitive test for the quantification of cell numbers in vitro.

Authors:  M Allen; P Millett; E Dawes; N Rushton
Journal:  Clin Mater       Date:  1994

2.  Quantitative assay of the lytic action of immune lymphoid cells on 51-Cr-labelled allogeneic target cells in vitro; inhibition by isoantibody and by drugs.

Authors:  K T Brunner; J Mauel; J C Cerottini; B Chapuis
Journal:  Immunology       Date:  1968-02       Impact factor: 7.397

3.  A quick and simple method for the quantitation of lactate dehydrogenase release in measurements of cellular cytotoxicity and tumor necrosis factor (TNF) activity.

Authors:  T Decker; M L Lohmann-Matthes
Journal:  J Immunol Methods       Date:  1988-11-25       Impact factor: 2.303

Review 4.  T-cell-directed cancer vaccines: the melanoma model.

Authors:  E Wang; G Q Phan; F M Marincola
Journal:  Expert Opin Biol Ther       Date:  2001-03       Impact factor: 4.388

5.  Identification of known and novel immunogenic T-cell epitopes from tumor antigens recognized by peripheral blood T cells from patients responding to IL-2-based treatment.

Authors:  Carmen Scheibenbogen; Yuansheng Sun; Ulrich Keilholz; Mingxia Song; Stefan Stevanovic; Anne Marie Asemissen; Dirk Nagorsen; Eckhard Thiel; Hans-Georg Rammensee; Dirk Schadendorf
Journal:  Int J Cancer       Date:  2002-03-20       Impact factor: 7.396

6.  Safety and efficacy of high-dose interleukin-2 therapy in patients with brain metastases.

Authors:  Lisa M Guirguis; James C Yang; Donald E White; Seth M Steinberg; David J Liewehr; Steven A Rosenberg; Douglas J Schwartzentruber
Journal:  J Immunother       Date:  2002 Jan-Feb       Impact factor: 4.456

7.  Therapeutic efficacy of IL-2-loaded hydrogels in a mouse tumor model.

Authors:  Cornelis J De Groot; Jenny A Cadée; Jan-Willem Koten; Wim E Hennink; Willem Den Otter
Journal:  Int J Cancer       Date:  2002-03-01       Impact factor: 7.396

Review 8.  Interleukin-2 as a therapeutic agent.

Authors:  N S Sule; R P Nerurkar; S Kamath
Journal:  J Assoc Physicians India       Date:  2001-09

Review 9.  Interleukin-12.

Authors:  M J Brunda
Journal:  J Leukoc Biol       Date:  1994-02       Impact factor: 4.962

10.  Interleukin 7 generates antitumor cytotoxic T lymphocytes against murine sarcomas with efficacy in cellular adoptive immunotherapy.

Authors:  D L Jicha; J J Mulé; S A Rosenberg
Journal:  J Exp Med       Date:  1991-12-01       Impact factor: 14.307

  10 in total
  4 in total

1.  A simple and sensitive method for measuring tumor-specific T cell cytotoxicity.

Authors:  Xinping Fu; Lihua Tao; Armando Rivera; Shana Williamson; Xiao-Tong Song; Nabil Ahmed; Xiaoliu Zhang
Journal:  PLoS One       Date:  2010-07-29       Impact factor: 3.240

2.  CD8(+) T cells induce platelet clearance in the liver via platelet desialylation in immune thrombocytopenia.

Authors:  Jihua Qiu; Xuena Liu; Xiaoqing Li; Xu Zhang; Panpan Han; Hai Zhou; Linlin Shao; Yu Hou; Yanan Min; Zhangyuan Kong; Yawen Wang; Yu Wei; Xinguang Liu; Heyu Ni; Jun Peng; Ming Hou
Journal:  Sci Rep       Date:  2016-06-20       Impact factor: 4.379

3.  Exploring Synergy in Combinations of Tumor-Derived Vaccines That Harbor 4-1BBL, OX40L, and GM-CSF.

Authors:  Andrea J Manrique-Rincón; Camila M Beraldo; Jessica M Toscaro; Marcio C Bajgelman
Journal:  Front Immunol       Date:  2017-09-19       Impact factor: 7.561

Review 4.  Metabolic Optimisation of Regulatory T Cells in Transplantation.

Authors:  Mo Atif; Audrey Mohr; Filomena Conti; Olivier Scatton; Guy Gorochov; Makoto Miyara
Journal:  Front Immunol       Date:  2020-09-02       Impact factor: 7.561

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.